Stocktoria
Vyome Holdings, Inc HIND
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-10-06
Vyome Holdings, Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $319,714 | $8.0M | $8.7M | $11.2M | $13.6M |
| Gross profit | $218,771 | $194,970 | $5.5M | $6.8M | $8.3M |
| R&D expense | $588,258 | $285,391 | $2.3M | $2.5M | $2.4M |
| SG&A expense | $2.4M | $898,572 | $7.5M | $14.1M | $8.9M |
| Operating income | -$10.5M | -$1.0M | -$15.4M | -$46.4M | -$57.9M |
| Income tax | — | $39,000 | $52,000 | -$380,000 | -$274,000 |
| Net income | -$10.3M | -$1.4M | -$11.4M | -$46.2M | -$63.1M |
| EPS (diluted) | $-4.86 | $-6001.39 | $-110.87 | $-108.90 | $-288.97 |
| Operating cash flow | -$3.7M | -$614,136 | -$17.0M | -$21.9M | -$15.4M |
| Cash & equivalents | $5.0M | $101,904 | $4.5M | $3.9M | $22.8M |
| Inventory | — | $2.5M | $3.7M | $3.6M | $3.0M |
| Total assets | $6.5M | $1.4M | $10.7M | $11.1M | $52.5M |
| Total liabilities | $2.7M | $5.8M | $4.0M | $7.5M | $8.2M |
| Shareholders' equity | $3.8M | -$4.4M | $6.7M | $3.7M | $44.3M |
Source: SEC EDGAR filings · CIK 0001427570 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.